Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function

被引:110
作者
Fryer, JD [1 ]
Lukas, RJ [1 ]
机构
[1] Barrow Neurol Inst, Div Neurobiol, Phoenix, AZ 85013 USA
关键词
nicotinic receptor; acetylcholine; fluoxetine; sertraline; paroxetine; nefazodone; venlafaxine; depression;
D O I
10.1046/j.1471-4159.1999.0721117.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nicotinic acetylcholine receptors (nAChRs) are diverse members of the neurotransmitter-gated ion channel superfamily and play critical roles in chemical signaling throughout the nervous system. The present study establishes for the first time the acute functional effects of sertraline (Zoloft), paroxetine (Paxil), nefazodone (Serzone), and venlafaxine (Effexor) on two human and one chick nAChR subtype. This study also confirms previous findings of nAChR functional block by fluoxetine (Prozac). Function of human muscle-type nAChR (alpha 1 beta gamma delta) in TE671/RD cells, human autonomic nAChR (alpha 3 beta 4 alpha 5 +/- beta 2) in SH-SY5Y neuroblastoma cells, or chick V274T mutant alpha 7-nAChR heterologously expressed in native nAChR-null SH-EPI epithelial cells was measured using Rb-86(+) efflux assays. Functional blockade of human muscle-type and autonomic nAChRs is produced by each of the drugs in the low to intermediate micromolar range, and functional blockade of chick V274T-alpha 7-nAChR is produced in the intermediate to high micromolar range. Functional blockade is insurmountable by increasing agonist concentrations at each nAChR subtype tested for each of these drugs, suggesting noncompetitive inhibition of nAChR function. These studies open the possibilities that nAChR subtypes in the brain could be targets for therapeutic antidepressants and could play roles in clinical depression.
引用
收藏
页码:1117 / 1124
页数:8
相关论文
共 45 条
[1]  
ALBUQUERQUE EX, 1980, MOL PHARMACOL, V18, P167
[2]   DEPRESSION AND THE DYNAMICS OF SMOKING - A NATIONAL PERSPECTIVE [J].
ANDA, RF ;
WILLIAMSON, DF ;
ESCOBEDO, LG ;
MAST, EE ;
GIOVINO, GA ;
REMINGTON, PL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (12) :1541-1545
[3]   CONTEMPORARY MANAGEMENT OF DEPRESSION [J].
ANDREWS, JM ;
NEMEROFF, CB .
AMERICAN JOURNAL OF MEDICINE, 1994, 97 :S24-S32
[4]  
ARITA M, 1987, J PHARMACOL EXP THER, V243, P342
[5]   CYTOCHALASIN MODULATION OF NICOTINIC CHOLINERGIC RECEPTOR EXPRESSION AND MUSCARINIC RECEPTOR FUNCTION IN HUMAN TE671/RD CELLS - A POSSIBLE FUNCTIONAL-ROLE OF THE CYTOSKELETON [J].
BENCHERIF, M ;
LUKAS, RJ .
JOURNAL OF NEUROCHEMISTRY, 1993, 61 (03) :852-864
[6]  
Bencherif M, 1995, J PHARMACOL EXP THER, V275, P1418
[7]   Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance [J].
Catterson, ML ;
Preskorn, SH .
PHARMACOLOGY & TOXICOLOGY, 1996, 78 (04) :203-208
[8]   NEURONS CAN MAINTAIN MULTIPLE CLASSES OF NICOTINIC ACETYLCHOLINE-RECEPTORS DISTINGUISHED BY DIFFERENT SUBUNIT COMPOSITIONS [J].
CONROY, WG ;
BERG, DK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (09) :4424-4431
[9]  
DEVANE CL, 1992, J CLIN PSYCHIAT, V53, P13
[10]   PHARMACOKINETICS OF THE NEWER ANTIDEPRESSANTS - CLINICAL RELEVANCE [J].
DEVANE, CL .
AMERICAN JOURNAL OF MEDICINE, 1994, 97 :S13-S23